Roth Capital Upgrades Tonix Pharma (TNXP) to Buy

August 18, 2017 5:34 AM EDT Send to a Friend
Roth Capital upgraded Tonix Pharma (NASDAQ: TNXP) from Neutral to Buy with a price target of $6.00.Analyst Scott Henry says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login